PTAB Nixes AbbVie Patent For $16B Blockbuster Humira
The Patent Trial and Appeal Board invalidated a key patent for AbbVie's top-selling immunosuppressive drug Humira on Thursday, handing a win to Boehringer Ingelheim in a pair of decisions that found...To view the full article, register now.
Already a subscriber? Click here to view full article